Walleye Capital’s Neurocrine Biosciences NBIX Stock Holding History

Walleye Capital’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-300	Closed	-$42.5K	–	4766
2025 Q4	$42.5K	Buy	+300	New	+$43.5K	﹤0.01%	4116
2025 Q3	–	Sell	-1,300	Closed	-$163K	–	4896
2025 Q2	$163K	Buy	+1,300	New	+$149K	﹤0.01%	3509
2024 Q4	–	Sell	-1,400	Closed	-$161K	–	5303
2024 Q3	$161K	Sell	1,400 -6,900	-83%	-$946K	﹤0.01%	4147
2024 Q2	$1.14M	Buy	8,300 +6,000	+261%	+$823K	﹤0.01%	2705
2024 Q1	$317K	Buy	+2,300	New	+$314K	﹤0.01%	3617
2020 Q2	–	Sell	-2,000	Closed	-$173K	–	846
2020 Q1	$173K	Sell	2,000 -18,200	-90%	-$1.78M	0.04%	476
2019 Q4	$2.17M	Buy	20,200 +4,600	+29%	+$482K	0.14%	174
2019 Q3	$1.41M	Buy	15,600 +3,000	+24%	+$280K	0.08%	325
2019 Q2	$1.06M	Buy	12,600 +1,500	+14%	+$123K	0.12%	242
2019 Q1	$978K	Buy	+11,100	New	+$928K	0.16%	172

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Walleye Capital's NBIX Position: Q1 2026 in Review

Walleye Capital sold out of Neurocrine Biosciences (NBIX) in Q1 2026, closing a stake of 90,325 shares — an estimated $12.8M sold.

Walleye Capital first reported a position in NBIX in Q3 2019 and held it in 17 quarters. The position peaked at $12.8M in Q4 2025. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

Walleye Capital reported no remaining Neurocrine Biosciences position as of Q1 2026 after selling out during the quarter.
Walleye Capital sold 90,325 Neurocrine Biosciences shares in Q1 2026, an estimated $12.8M.
Walleye Capital first reported a position in Neurocrine Biosciences in Q3 2019 and held it in 17 quarters.
Walleye Capital's Neurocrine Biosciences position peaked at $12.8M in Q4 2025.
694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.